Overview of Clavis

Property	Description
Active Ingredients	Amoxicillin and Clavulanic Acid
Forms	Tablets, Oral Suspension, Injection
Pharmacological Class	Beta-lactam Antibiotic (Penicillin)
Common Type	Broad-spectrum combination product
Origin	Semisynthetic

What Type of Antibiotic is Clavis (Co-amoxiclav)?

Clavis is a prescription-only medication (Rx) known generically as Co-amoxiclav or Amoxicillin/Clavulanic Acid, which belongs to the Beta-lactam antibiotic class. It is a derivative of the penicillin family, making it a semisynthetic compound that works to eliminate harmful bacteria responsible for infections. The combination is globally recognized for its ability to treat infections where bacterial resistance is suspected or confirmed, and is included on the World Health Organization's Essential Medicines List (WHO).

Unlike basic, single-agent penicillins, Co-amoxiclav is classified as a combination product. This formulation is typically positioned for patient groups ranging from children, using the oral suspension, to adults requiring hospital-level care with the intravenous preparation. Popular commercial formulations containing this INN combination include Augmentin and Moxclav.

What is Clavis Made of and How Does the Combination Work?

The formulation is composed of two primary active ingredients / chemical substances: Amoxicillin trihydrate and Potassium Clavulanate (Clavulanic Acid). Amoxicillin performs the bactericidal action by inhibiting bacterial cell wall formation. Clavulanic Acid serves a protective role as a β-lactamase inhibitor. This compound effectively neutralizes the β-lactamase enzymes that many bacteria produce to chemically destroy Amoxicillin.

By defending the primary antibiotic, the combination is able to achieve powerful broad-spectrum antibiotic action against a wider range of resistant pathogens. This approach is necessary to treat infections caused by β-lactamase-producing bacteria, meaning the drug is designed to work even when common bacteria are trying to protect themselves.

Available Forms of Co-amoxiclav

Co-amoxiclav is supplied in several drug forms / pharmaceutical preparations for both oral and intravenous use. Common formats include film-coated tablets and a liquid oral suspension, both designed for oral intake. For urgent or severe cases, the medicine is also available as a powder for injection, which is prepared by healthcare professionals for direct use as an intravenous preparation.

Regulatory References

Essential Medicines List (WHO)

What side effects are possible with Clavis?

Officially Documented Adverse Reactions

The safety profile of Co-amoxiclav is defined by government regulatory documents, which classify adverse reactions by frequency and affected body system. The most Very Common side effect, occurring in more than 1 in 10 patients, is diarrhoea (in adults).

Common reactions, affecting up to 1 in 10 patients, include mucocutaneous candidosis, nausea, and vomiting. Uncommon effects involve rises in liver enzymes (AST/ALT), headache, dizziness, and mild skin reactions like pruritus.

Serious Safety and Population Considerations

Serious adverse reactions, though rare or very rare, are officially documented in prescribing information. These include life-threatening hypersensitivity reactions such as anaphylaxis and angioedema, which may occur at the start of treatment. Severe cutaneous reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also listed.

Safety constraints and warnings focus heavily on the hepatobiliary system. Hepatitis and cholestatic jaundice are rare but potentially fatal serious events, particularly documented in older adults and males. These hepatic adverse reactions may manifest not only during treatment but also shortly after discontinuation. The drug is contraindicated in individuals with a history of penicillin allergy or previous Co-amoxiclav-associated hepatic dysfunction. For patients with renal impairment, the need for dose adjustment is officially noted to mitigate the risk of adverse effects like convulsions.

Overdose and Emergency Response

The official regulatory profile for an overdose of Clavis (Amoxicillin/Clavulanic Acid) outlines specific clinical manifestations and mandated emergency actions. Documented overdose presentations primarily involve gastrointestinal symptoms such as vomiting, diarrhea, and general stomach upset, often accompanied by sleepiness and disturbances of fluid and electrolyte balances.

Overdose carries the potential for severe neurological and renal outcomes. The most serious documented manifestations include convulsions (fits) and the risk of amoxicillin crystalluria, which can, in rare cases, lead to acute renal failure. Patients with pre-existing impaired renal function are noted to be at an increased risk for convulsions following over-ingestion.

In the event of a suspected overdose, regulatory guidance requires that patients seek immediate medical attention. Official health authority advice specifies contacting emergency services immediately if a significant over-ingestion is suspected, such as taking two or more extra doses, or if the overdose results in a fit.

Treatment measures described in the regulatory labeling are primarily symptomatic and supportive. Management focuses on maintaining adequate fluid intake and addressing electrolyte balance. Haemodialysis is documented as a procedural measure that can effectively remove the active components from the systemic circulation. For monitored patients with bladder catheters, regulatory information also mandates a regular check of catheter patency to prevent obstruction caused by crystalluria.

Therapeutic Uses of Clavis

Quick Facts

Condition Supported: Acute, painful musculoskeletal conditions
Therapeutic Role: Helps alleviate muscle spasms in the affected areas
Use Context: Intended to be used as a complement to rest and physical therapy
Duration of Use: Generally reserved for short periods, often up to two or three weeks

What Clavis Treats: Main Uses and Benefits

Clavis is a medication used in the context of acute, painful musculoskeletal conditions. Its authorized role is to help relieve muscle spasms that may occur in the affected body areas. It is generally utilized for a short duration of time, often not exceeding two or three weeks, as these muscle-related conditions tend to resolve within that timeframe.

The medication is designed to function as an adjunct to other established therapeutic measures. This means Clavis is typically prescribed alongside rest and physical therapy to manage the condition. Its primary function is to address the local muscular hyperactivity associated with the discomfort and to support the patient's capacity for movement during the acute phase.

Clavis is a centrally acting skeletal muscle relaxant. It is not indicated for the treatment of spasticity and is generally reserved for patients who have not responded sufficiently to other measures like rest and non-pharmacologic interventions. Consult a healthcare provider for a thorough review of the medication's appropriate usage.

Eligibility and Restrictions for Use

Clavis (Amoxicillin and Clavulanate Potassium) is approved for use only in patients with a specific bacterial infection as listed in the official regulatory documentation. Its eligibility profile is strictly defined by government health authorities.

Populations Who Must Not Use Clavis (Contraindicated)

Use is contraindicated (must not be used) in patients with the following conditions, as stated in the regulatory label:

A known history of a severe hypersensitivity reaction to Amoxicillin, Clavulanate, or any other penicillin-class antibiotic.
A prior history of idiosyncratic drug-induced hepatic injury (liver damage) associated with the use of Amoxicillin-Clavulanate.

Eligibility Constraints and Special Populations

Official documents require caution and close monitoring for certain patient groups:

Population	Eligibility Constraint
Renal Impairment	Caution is required; patients with severe impairment (GFR < 30 mL/min) typically require a dosage adjustment to prevent accumulation.
Hepatic Impairment	Caution is necessary due to the risk of liver injury; close monitoring of liver function is required during and after administration.
Infectious Mononucleosis	Use should be avoided, as a high incidence of rash is associated with penicillin use in these patients.
Pediatric Patients	Use is permitted according to approved indications and weight-based dosing; the oral suspension is the recommended form for younger children.

Eligibility is limited to an approved indication, and the medicine is not intended for use against bacteria that are confirmed to not produce beta-lactamase.

What should I know about interactions with other medicines?

The official interaction profile for Clavis (Amoxicillin/Clavulanic Acid) is defined by pharmacokinetic and pharmacodynamic effects documented in regulatory sources.

Pharmacokinetic and Exposure Alterations

Co-administration with the uricosuric agent Probenecid is officially noted to decrease the renal tubular secretion of the amoxicillin component. This transporter-mediated effect results in increased and prolonged blood concentrations of amoxicillin, and concurrent use is generally not recommended by regulatory sources. The drug may also affect the systemic exposure of other medicines; official prescribing information states a potential for reduced efficacy of combined oral contraceptives due to interference with estrogen reabsorption. Furthermore, Clavis may reduce the renal clearance of Methotrexate, which is associated with increased systemic exposure to Methotrexate.

Pharmacodynamic and Administration Constraints

For patients receiving Oral Anticoagulants (such as Warfarin), co-administration may result in the prolongation of prothrombin time (INR), a pharmacodynamic effect requiring monitoring of coagulation status. Concomitant use with Allopurinol is linked to an increased incidence of skin rash. To optimize absorption and minimize potential gastrointestinal intolerance, the regulatory labeling specifies a timing condition that Clavis should be taken at the start of a meal.

Mechanism of Action

Clavis exerts its action through a specialized, two-component bactericidal mechanism, directly targeting the cell-building processes of bacterial cells. The primary mechanism is executed by Amoxicillin acting as a direct and irreversible inhibitor of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for building the rigid protective wall. By covalently binding to the active site of the PBPs, Amoxicillin blocks the final cross-linking of the peptidoglycan layer. This failure in construction leads to a loss of cell integrity, triggering an autolytic cascade that causes the bacterial cell to rupture and die (lysis).

The combination mechanism addresses resistance common in bacteria that produce beta-lactamase enzymes to chemically destroy Amoxicillin. Clavulanic Acid counteracts this resistance mechanism by acting as a suicide inhibitor that preferentially and irreversibly binds to these beta-lactamase enzymes. This complementary action protects the Amoxicillin molecule from destruction, ensuring its functional availability to reach and inhibit the PBPs. This synergy is the mechanistic requirement for the primary mechanism to function against beta-lactamase-producing bacteria.

Dosage and Administration Information

How to Use Clavis (Amoxicillin/Clavulanic Acid)

The administration of Clavis is determined by the patient's clinical scenario, with officially approved methods utilizing both oral and intravenous (IV) routes. Oral forms include film-coated tablets and liquid suspensions, while the IV preparation is reserved for severe infections or hospital settings.

Oral administration of Clavis is specifically tied to meal timing: the medicine must be taken at the start of a meal to enhance the absorption of the clavulanic acid component and minimize the possibility of gastrointestinal upset. The standard course of treatment for Clavis should not exceed 14 days without a mandatory clinical review of the patient's condition.

Standard Administration and Schedule

Official regimens are based on the amoxicillin dosage and require administration at fixed intervals, typically two or three times daily.

Dosing Parameter	Official Requirement
Standard Frequency	Every 8 hours or every 12 hours, depending on the specific product strength and infection severity.
Course Duration	Treatment should not exceed 14 days and requires clinical review if continued past this limit.

Handling and Population Adjustments

The manner of intake depends on the formulation; for instance, extended-release tablets must be swallowed whole and must not be crushed or chewed. Dosing requires specific adjustment for patients with reduced kidney function (Creatinine Clearance ≤ 30 mL/min) as the drug is primarily cleared through the renal system. In these cases, specific high-dose forms are restricted to prevent excessive accumulation.

Recent Clinical Evidence

Elacytarabine (CP-4055) in Acute Myeloid Leukemia (AML)

Elacytarabine, a patented lipid-conjugated derivative of the established chemotherapy agent cytarabine, was the lead product of Clavis Pharma and the focus of its most significant clinical development program. The drug was designed to improve uptake into cancer cells, potentially offering an effective treatment option for certain patient populations.

Key Clinical Findings

Trial Phase	Indication / Patient Group	Outcome Summary
Phase II	Relapsed/Refractory Late-Stage AML	Initial results suggested encouraging outcomes in median survival and remission rates when compared to previously published data for similar patient populations.
Phase II	Early-Stage AML (post-failed initial therapy)	The drug, when used in combination with idarubicin, showed promising clinical activity, with approximately 50% of evaluated patients achieving complete remission or complete remission with incomplete blood count recovery (CR/CRi).
Phase III (CLAVELA)	Late-Stage AML	This randomized, controlled, pivotal trial sought to confirm the survival benefit observed in the earlier Phase II data. However, the study results were negative, and the primary endpoint was not met.

The research suggested that the efficacy of the parent drug, cytarabine, is linked to the cellular expression of the hENT1 transport protein. Elacytarabine was developed to overcome potential resistance in patients with low hENT1 expression. Studies investigating this biomarker suggested that elacytarabine's activity was independent of the patient's hENT1 status, supporting its potential utility in patients who may not respond well to standard cytarabine-based therapies. Despite the promising initial results, the confirmatory Phase III trial did not establish the therapeutic benefit of elacytarabine for the specific late-stage AML indication studied.

Frequently Asked Questions (FAQ)

Common questions about Clavis (FAQ)

Q: Are there any specific vitamins or supplements that are known to interact with Clavis?

Regulatory documents focus on known drug-drug interactions with specific prescription agents like Warfarin and Probenecid. Official prescribing information typically does not detail interactions with every common vitamin or general dietary supplement. Information about all concurrent products a patient is taking is important for their prescriber to review.

Q: What is the process for health monitoring while a person is taking Clavis?

Official documents recommend monitoring certain health markers for specific patient groups. For example, monitoring of liver and kidney function is suggested during prolonged or high-dose therapy, and blood clotting tests (INR) are monitored if the patient takes oral anticoagulants. Routine, generalized monitoring for all patients is not universally mandated by the label.

Q: Are there any documented effects of Clavis on common blood or lab test results?

According to official product information, the drug may affect certain laboratory results. Specifically, documented effects include possible increases in liver enzyme levels (AST and ALT), and it may prolong Prothrombin Time (INR) in patients who are also taking oral anticoagulant medication.

Q: What specific symptoms or conditions is Clavis not intended to treat?

The drug is an antibiotic and is indicated only for treating infections caused by specific, susceptible types of bacteria. Official guidance indicates the medication is not effective against viral infections, such as the common cold or flu, or against any non-infectious conditions.

Q: Is Clavis considered a controlled substance by regulatory bodies?

Official drug classification documents confirm that Clavis (Amoxicillin/Clavulanic Acid) is defined as a prescription-only medication (Rx). However, it is not classified as a controlled substance by major regulatory bodies.

Q: How long after starting Clavis do studies suggest initial effects can be seen?

Studies and official information indicate that the medication begins its action against bacteria soon after the first dose. While the exact timing can vary depending on the type and severity of the infection, initial symptom improvement may begin within a few days of starting therapy, although this timing can vary for each individual.

Q: Is it true that Clavis takes several weeks to reach its full documented effect?

The full therapeutic effect of eliminating the target bacterial population is generally achieved within the defined course of treatment, which is typically 5 to 14 days. The medication is not designed to take several weeks to reach its full potential. Official information states that the medication is typically prescribed for a full course of therapy.

Q: How long does Clavis typically stay in the body after the last dose?

The official pharmacokinetics section indicates that both the amoxicillin and clavulanic acid components have a short half-life, typically around 1 to 1.3 hours. For most people with normal kidney function, detectable levels of the drug are cleared from the bloodstream within approximately 8 to 12 hours after the last dose.

Q: What happens if a person misses a dose of Clavis? (General factual clarification)

According to regulatory-backed patient instructions, if a dose is missed, patient instructions describe taking it as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped entirely. The patient instructions specify that a double dose must not be used to compensate for a missed dose.

Q: Are there any official warnings about consuming alcohol while taking Clavis?

Official sources state there is no known specific chemical interaction between the drug and alcohol that causes a dangerous reaction. However, alcohol consumption may worsen common side effects like nausea or dizziness, and may be associated with an increased risk of liver side effects.

Q: What is the official guidance regarding Clavis and common drinks like coffee or tea?

Official guidance contained within patient information leaflets confirms that there are no specific dietary restrictions related to common drinks like coffee or tea. Patients can typically maintain their usual eating and drinking habits while taking this medication.

Q: Can Clavis be taken with common over-the-counter pain medicines?

Regulatory documents do not list a major, direct interaction with common over-the-counter (OTC) pain relievers like ibuprofen or acetaminophen. However, combining them with Clavis may increase the risk of certain additive side effects, particularly gastrointestinal upset.

Q: Is it possible to take Clavis alongside blood pressure medication?

The official drug interaction sections do not list blood pressure medications as a class with a known severe interaction or contraindication. The official information focuses on specific agents like oral anticoagulants, rather than providing general guidance on blood pressure medications.

Q: Is fatigue a documented common side effect of Clavis?

Fatigue is not categorized as one of the most common adverse reactions listed in the official safety profile. However, it has been reported as a less frequent symptom, sometimes noted in the context of other adverse events like rare hepatic injury.

Q: Do the side effects of Clavis usually go away over time?

Studies and regulatory summaries indicate that most common side effects, such as diarrhea and nausea, are generally mild and self-limited. These reactions typically resolve after the completion of the full course of treatment.

Q: Is there a documented risk of physical dependence or withdrawal symptoms with Clavis?

As a beta-lactam antibiotic, the regulatory documents explicitly do not list a risk of physical dependence or clinically recognized withdrawal symptoms. The medication does not affect the central nervous system in a way that leads to dependence.

Q: How should a person report a suspected side effect of Clavis to the authorities?

Official government regulatory agencies provide specific systems for reporting suspected side effects. Patients and healthcare professionals can submit reports directly to organizations such as the FDA’s MedWatch Program in the United States.

Q: What is the official regulatory statement about using Clavis during pregnancy?

Official regulatory sources, such as the FDA, classify this drug as Pregnancy Category B. The official label states that the drug's use during pregnancy is reserved for situations where the treating clinician determines the potential benefit justifies the potential risk, due to limited controlled human studies.

Q: Does Clavis affect the ability to drive or operate machinery, according to official warnings?

Official warnings advise that the medication may cause side effects, such as dizziness, allergic reactions, or convulsions, that could impair the ability to drive or operate heavy machinery. Official warnings state that caution should be exercised if these side effects occur.

Q: Where can a person find the official regulatory review documents for Clavis?

Official regulatory review documents, including the approved prescribing label, clinical reviews, and assessment reports, are made available to the public. These can typically be accessed on the websites of national regulatory bodies, such as the US FDA or the European Medicines Agency (EMA).

Q: What is the regulatory definition of the term 'half-life' when referring to Clavis?

The term 'half-life' is defined in the drug's official Pharmacokinetics section. It refers to the time it takes for the concentration of the drug in the body to be reduced by precisely one-half of its maximum level.

Q: Is Clavis known to affect sleep patterns?

The regulatory adverse reaction profile does list central nervous system effects. Specifically, official documents report difficulty sleeping (insomnia) as a potential side effect, along with other reactions such as agitation and dizziness.

How should Clavis be stored and disposed of?

How to Store and Dispose of Clavis?

Official regulatory guidelines strictly define the storage requirements for Clavis (Co-amoxiclav) based on its pharmaceutical form, focusing on temperature and stability.

Required Storage Conditions

Product Form	Temperature Requirement	Stability Constraint
Dry Powder (Tablets/Suspension)	Store at or below 25 C (77 F).	Dispense and keep in the original container.
Oral Suspension (Reconstituted)	Must be stored under refrigeration.	Discard any unused portion after 7 to 10 days.

Handling and Protection

The liquid suspension must be shaken well before each use. Storage rules prohibit keeping the reconstituted suspension at room temperature or freezing it. For all forms, proper disposal of unused or expired medication should follow local pharmaceutical waste collection procedures.

Clavis